HCAR 2
Alternative Names: H2CAR; HCAR-2Latest Information Update: 25 Jul 2025
At a glance
- Originator ImmunoACT
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Multiple myeloma
Most Recent Events
- 25 Jul 2025 Clinical trials in Multiple myeloma (Parenteral), Prior to July 2025 (ImmunoACT pipeline, July 2025)
- 25 Jul 2025 ImmunoACT plans to commercialise the drug candidate for multiple myeloma in 2025 (ImmunoACT pipeline, July 2025)
- 07 Dec 2024 Pharmacodynamics and adverse event data from a preclinical trial in Multiple myeloma presented at the 66th American Society of Hematology Annual Meeting and Exposition 2024 (ASH-Hem-2024)